Who makes Treatment B: JW0107 1 tablet?

Treatment B: JW0107 1 tablet is developed by JW Pharmaceutical.

What development phase is Treatment B: JW0107 1 tablet in?

Treatment B: JW0107 1 tablet is in Phase 1.

Last reviewed 2026-05-13 · How we verify

Treatment B: JW0107 1 tablet

JW Pharmaceutical · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	Treatment B: JW0107 1 tablet
Also known as	Administration alone of 1 tablet of JW0107
Sponsor	JW Pharmaceutical
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Treatment B: JW0107 1 tablet CI brief — competitive landscape report
Treatment B: JW0107 1 tablet updates RSS · CI watch RSS
JW Pharmaceutical portfolio CI